Back to homepage

Nephrology and Urology

NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK

Authors: Helene Cawston, Francois Bourhis, Jennifer Eriksson, Pierfrancesco Ruffo, Paolo D’Agostino, Marco Turini, Lee Schwartzberg, Alistair McGuire

Despite study limitations (study setting, time horizon, utility measure), the results suggest NEPA is cost effective for preventing CINV associated with HEC and MEC in the UK.

More

Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia

Authors: Rosamund J Wilson, J Brian Copley

Calcium acetate/calcium carbonate phosphate binders, taken to control serum phosphate levels, may result in high levels of elemental calcium intake.

More

Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease

Authors: Michael Keith, Patricia de Sequera, Francois Clair, Riccardo Pedersini

The aim of this survey was to investigate satisfaction with, preference for, and adherence to lanthanum carbonate oral powder in patients with end-stage renal disease (ESRD). The authors concluded that patients with ESRD report increased satisfaction with and preference for lanthanum carbonate powder over other formulations, suggesting that lanthanum carbonate powder is more convenient and easier to use than other formulations.

More

Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease

Authors: Christopher M Blanchette, Caihua Liang, Deborah P Lubeck, Britt Newsome, Sandro Rossetti, Xiangmei Gu, Benjamin Gutierrez, Nancy D Lin

Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic disorder characterized by the development of numerous kidney cysts that result in kidney failure. The results of this study suggest that distribution of patients by age at transition to next stage may be useful for identification of ADPKD patients at risk of rapid progression.

More

Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function

Authors: Christopher M Blanchette, Anthony P Nunes, Nancy D Lin, Kathleen M Mortimer, Joshua Noone, Krishna Tangirala, Stephen Johnston, Benjamin Gutierrez

Risk evaluation and mitigation strategies (REMS), as mandated by the FDA for medications with the potential for harm, are increasingly incorporating rigid protocols for patient evaluation, but little is known about compliance with these programs. This study assessed adherence to liver function test (LFT) requirements included in the REMS program for bosentan and the results suggest that the program may not have adequately guaranteed adherence to monthly monitoring of LFTs.

More